311 related articles for article (PubMed ID: 33799647)
1. Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease.
Moriggi M; Capitanio D; Torretta E; Barbacini P; Bragato C; Sartori P; Moggio M; Maggi L; Mora M; Gelfi C
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799647
[TBL] [Abstract][Full Text] [Related]
2. Effects of short-to-long term enzyme replacement therapy (ERT) on skeletal muscle tissue in late onset Pompe disease (LOPD).
Ripolone M; Violano R; Ronchi D; Mondello S; Nascimbeni A; Colombo I; Fagiolari G; Bordoni A; Fortunato F; Lucchini V; Saredi S; Filosto M; Musumeci O; Tonin P; Mongini T; Previtali S; Morandi L; Angelini C; Mora M; Sandri M; Sciacco M; Toscano A; Comi GP; Moggio M
Neuropathol Appl Neurobiol; 2018 Aug; 44(5):449-462. PubMed ID: 28574618
[TBL] [Abstract][Full Text] [Related]
3. Autophagy and mistargeting of therapeutic enzyme in skeletal muscle in Pompe disease.
Fukuda T; Ahearn M; Roberts A; Mattaliano RJ; Zaal K; Ralston E; Plotz PH; Raben N
Mol Ther; 2006 Dec; 14(6):831-9. PubMed ID: 17008131
[TBL] [Abstract][Full Text] [Related]
4. Rare Variants in Autophagy and Non-Autophagy Genes in Late-Onset Pompe Disease: Suggestions of Their Disease-Modifying Role in Two Italian Families.
Napolitano F; Bruno G; Terracciano C; Franzese G; Palomba NP; Scotto di Carlo F; Signoriello E; De Blasiis P; Navarro S; Gialluisi A; Melone MAB; Sampaolo S; Esposito T
Int J Mol Sci; 2021 Mar; 22(7):. PubMed ID: 33807278
[TBL] [Abstract][Full Text] [Related]
5. Clinical and molecular aspects of 30 patients with late-onset Pompe disease (LOPD): unusual features and response to treatment.
Montagnese F; Barca E; Musumeci O; Mondello S; Migliorato A; Ciranni A; Rodolico C; De Filippi P; Danesino C; Toscano A
J Neurol; 2015; 262(4):968-78. PubMed ID: 25673129
[TBL] [Abstract][Full Text] [Related]
6. Effect of enzyme replacement therapy in late onset Pompe disease: open pilot study of 48 weeks follow-up.
Park JS; Kim HG; Shin JH; Choi YC; Kim DS
Neurol Sci; 2015 Apr; 36(4):599-605. PubMed ID: 25388776
[TBL] [Abstract][Full Text] [Related]
7. Gene Therapy for Pompe Disease: The Time is now.
Colella P; Mingozzi F
Hum Gene Ther; 2019 Oct; 30(10):1245-1262. PubMed ID: 31298581
[TBL] [Abstract][Full Text] [Related]
8. Reduction of Autophagic Accumulation in Pompe Disease Mouse Model Following Gene Therapy.
McCall AL; Stankov SG; Cowen G; Cloutier D; Zhang Z; Yang L; Clement N; Falk DJ; Byrne BJ
Curr Gene Ther; 2019; 19(3):197-207. PubMed ID: 31223086
[TBL] [Abstract][Full Text] [Related]
9. The value of muscle biopsies in Pompe disease: identifying lipofuscin inclusions in juvenile- and adult-onset patients.
Feeney EJ; Austin S; Chien YH; Mandel H; Schoser B; Prater S; Hwu WL; Ralston E; Kishnani PS; Raben N
Acta Neuropathol Commun; 2014 Jan; 2():2. PubMed ID: 24383498
[TBL] [Abstract][Full Text] [Related]
10. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease.
Liang Q; Vlaar EC; Pijnenburg JM; Rijkers E; Demmers JAA; Vulto AG; van der Ploeg AT; van Til NP; Pijnappel WWMP
J Proteomics; 2024 Jan; 291():105037. PubMed ID: 38288553
[TBL] [Abstract][Full Text] [Related]
11. Pompe Disease: New Developments in an Old Lysosomal Storage Disorder.
Meena NK; Raben N
Biomolecules; 2020 Sep; 10(9):. PubMed ID: 32962155
[TBL] [Abstract][Full Text] [Related]
12. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers.
Raben N; Fukuda T; Gilbert AL; de Jong D; Thurberg BL; Mattaliano RJ; Meikle P; Hopwood JJ; Nagashima K; Nagaraju K; Plotz PH
Mol Ther; 2005 Jan; 11(1):48-56. PubMed ID: 15585405
[TBL] [Abstract][Full Text] [Related]
13. Insight into the phenotype of infants with Pompe disease identified by newborn screening with the common c.-32-13T>G "late-onset" GAA variant.
Rairikar MV; Case LE; Bailey LA; Kazi ZB; Desai AK; Berrier KL; Coats J; Gandy R; Quinones R; Kishnani PS
Mol Genet Metab; 2017 Nov; 122(3):99-107. PubMed ID: 28951071
[TBL] [Abstract][Full Text] [Related]
14. An integrative correlation of myopathology, phenotype and genotype in late onset Pompe disease.
Kulessa M; Weyer-Menkhoff I; Viergutz L; Kornblum C; Claeys KG; Schneider I; Plöckinger U; Young P; Boentert M; Vielhaber S; Mawrin C; Bergmann M; Weis J; Ziagaki A; Stenzel W; Deschauer M; Nolte D; Hahn A; Schoser B; Schänzer A
Neuropathol Appl Neurobiol; 2020 Jun; 46(4):359-374. PubMed ID: 31545528
[TBL] [Abstract][Full Text] [Related]
15. Comparison of recent pivotal recommendations for the diagnosis and treatment of late-onset Pompe disease using diagnostic nodes-the Pompe disease burden scale.
Hundsberger T; Schoser B; Leupold D; Rösler KM; Putora PM
J Neurol; 2019 Aug; 266(8):2010-2017. PubMed ID: 31104135
[TBL] [Abstract][Full Text] [Related]
16. Observational clinical study of 22 adult-onset Pompe disease patients undergoing enzyme replacement therapy over 5years.
Stepien KM; Hendriksz CJ; Roberts M; Sharma R
Mol Genet Metab; 2016 Apr; 117(4):413-8. PubMed ID: 26873529
[TBL] [Abstract][Full Text] [Related]
17. Autophagy in skeletal muscle: implications for Pompe disease.
Shea L; Raben N
Int J Clin Pharmacol Ther; 2009; 47 Suppl 1(Suppl 1):S42-7. PubMed ID: 20040311
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Benefit of Autophagy Modulation in Pompe Disease.
Lim JA; Sun B; Puertollano R; Raben N
Mol Ther; 2018 Jul; 26(7):1783-1796. PubMed ID: 29804932
[TBL] [Abstract][Full Text] [Related]
19. The emerging phenotype of late-onset Pompe disease: A systematic literature review.
Chan J; Desai AK; Kazi ZB; Corey K; Austin S; Hobson-Webb LD; Case LE; Jones HN; Kishnani PS
Mol Genet Metab; 2017 Mar; 120(3):163-172. PubMed ID: 28185884
[TBL] [Abstract][Full Text] [Related]
20. Hypersensitivity infusion-associated reactions induced by enzyme replacement therapy in a cohort of patients with late-onset Pompe disease: An experience from the French Pompe Registry.
Lessard LER; Tard C; Salort-Campana E; Sacconi S; Béhin A; Bassez G; Orlikowski D; Merle P; Nollet S; Gallay L; Bérard F; Robinson P; Bouhour F; Laforêt P
Mol Genet Metab; 2023 Jul; 139(3):107611. PubMed ID: 37285781
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
